-
1
-
-
0033517302
-
The effect of spironolactone on morbidity and mortality in patients with severe heart failure
-
MD, MD, MD, MD, MD
-
Pitt B MD, Zannad F MD, Remme WJ MD, Cody R MD, Castaigne A MD, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341(10):709-717
-
(1999)
N Engl J Med
, vol.341
, Issue.10
, pp. 709-717
-
-
Pitt, B.1
Zannad, F.2
Remme, W.J.3
Cody, R.4
Castaigne, A.5
-
2
-
-
0037417252
-
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
-
DOI 10.1056/NEJMoa030207
-
Pitt B MD, Zannad F MD, Remme WJ MD, Neaton J PhD, Martinez FMD, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309-1321 (Pubitemid 36384098)
-
(2003)
New England Journal of Medicine
, vol.348
, Issue.14
, pp. 1309-1321
-
-
Pitt, B.1
Remme, W.2
Zannad, F.3
Neaton, J.4
Martinez, F.5
Roniker, B.6
Bittman, R.7
Hurley, S.8
Kleiman, J.9
Gatlin, M.10
-
3
-
-
10644242516
-
Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure
-
DOI 10.1016/j.ahj.2004.10.005, PII S0002870304007501
-
Tamirisa KP MD, Aaronson KD MD, MS, Koelling TM MD. Spironolactone- induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004;148(6):971-978 (Pubitemid 39646969)
-
(2004)
American Heart Journal
, vol.148
, Issue.6
, pp. 971-978
-
-
Tamirisa, K.P.1
Aaronson, K.D.2
Koelling, T.M.3
-
4
-
-
3442886513
-
Rates of Hyperkalemia after publication of the randomized Aldactone evaluation study
-
MD, PhD, Pharm. D, MPH, MD, BA, PhD
-
Juurlink DN MD, PhD, Mamdani MM Pharm. D, MPH, Lee DS MD, Kopp A BA, Austin PC PhD, et al.: Rates of Hyperkalemia after publication of the randomized Aldactone evaluation study. N Engl J Med 2004;351(6):543-551
-
(2004)
N Engl J Med
, vol.351
, Issue.6
, pp. 543-551
-
-
Juurlink, D.N.1
Mamdani, M.M.2
Lee, D.S.3
Kopp, A.4
Austin, P.C.5
-
5
-
-
0035870772
-
Life-threatening hyperkalemia during combined therapy with angiotensin converting enzyme inhibitors and spironolactone: An analysis of 25 cases
-
MD, MD, PhD, MD, MD, PhD
-
Schepkens H MD, Vanholder R MD, PhD, Billiouw JM MD, Lameire N MD, PhD: Life-threatening hyperkalemia during combined therapy with angiotensin converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med 2001; 110: 438-441
-
(2001)
Am J Med
, vol.110
, pp. 438-441
-
-
Schepkens, H.1
Vanholder, R.2
Billiouw, J.M.3
Lameire, N.4
-
6
-
-
0035315810
-
Serious adverse events experienced by patients with chronic heart failure taking spironolactone
-
MD, MD
-
Berry C MD, McMurray JJ MD. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001;85:E8
-
(2001)
Heart
, vol.85
-
-
Berry, C.1
McMurray, J.J.2
-
7
-
-
33751114892
-
Reports of hyperkalemia after publication of RALES - A pharmacovigilance study
-
MD, MPH, MD, Pharm.D, PhD
-
Hauben M MD, MPH, Reich L MD, Gerrits CM Pharm.D, PhD. Reports of hyperkalemia after publication of RALES-a pharmacovigilance study. Pharmacoepidemiol Drug Saf 2006; 15(11): 775-783
-
(2006)
Pharmacoepidemiol Drug Saf
, vol.15
, Issue.11
, pp. 775-783
-
-
Hauben, M.1
Reich, L.2
Gerrits, C.M.3
-
8
-
-
0242637043
-
Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: Retrospective study
-
Svensson M MD, Gustafsson F MD, Galatius S MD, Hildebrandt PR, MD, Atar D MD. Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ 2003;327:1141-1142 (Pubitemid 37421809)
-
(2003)
British Medical Journal
, vol.327
, Issue.7424
, pp. 1141-1142
-
-
Svensson, M.1
Gustafsson, F.2
Galatius, S.3
Hildebrandt, P.R.4
Atar, D.5
-
9
-
-
33646484997
-
Appropriateness of spironolactone prescribing in heart failure patients: A population-based study
-
MD, MD, PhD, Pharm.D, MPH, MD, MSc
-
Ko DT MD, Juurlink DN MD, PhD, Mamdani MM Pharm.D, MPH, You JJ MD, Wang JT MSc, et al.: Appropriateness of spironolactone prescribing in heart failure patients: A population-based study. J Card Fail 2006;12(3):205-210
-
(2006)
J Card Fail
, vol.12
, Issue.3
, pp. 205-210
-
-
Ko, D.T.1
Juurlink, D.N.2
Mamdani, M.M.3
You, J.J.4
Wang, J.T.5
-
10
-
-
20044379730
-
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology
-
DOI 10.1093/eurheartj/ehi044
-
Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, et al.: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416 (Pubitemid 40283098)
-
(2005)
European Heart Journal
, vol.26
, Issue.4
, pp. 384-416
-
-
Nieminen, M.S.1
Bohm, M.2
Cowie, M.R.3
Drexler, H.4
Filippatos, G.S.5
Jondeau, G.6
Hasin, Y.7
Lopez-Sendon, J.8
Mebazaa, A.9
Metra, M.10
Rhodes, A.11
Swedberg, K.12
-
11
-
-
0142117284
-
Aldosterone blockade in patients with systolic left ventricular dysfunction
-
MD
-
Pitt B MD: Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 2003;108:1790-1794
-
(2003)
Circulation
, vol.108
, pp. 1790-1794
-
-
Pitt, B.1
-
12
-
-
0034651798
-
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure
-
MBChB, MRCP, MD, FRCP
-
Farquharson CA MBChB, MRCP, Struthers AD MD, FRCP: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:1722-1728
-
(2000)
Circulation
, vol.101
, pp. 1722-1728
-
-
Farquharson, C.A.1
Struthers, A.D.2
-
13
-
-
0035370038
-
Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure
-
MRCP, SD MD, FRCP, MD, FRCP, FESC
-
Yee KM MRCP, Pringle SD MD, FRCP, Struthers AD MD, FRCP, FESC: Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2002;37(7):1800-1807
-
(2002)
J Am Coll Cardiol
, vol.37
, Issue.7
, pp. 1800-1807
-
-
Yee, K.M.1
Pringle2
Struthers, A.D.3
-
14
-
-
0035168937
-
Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction
-
MD, FACC, FESC, MD, MD, MD
-
Modena MG MD, FACC, FESC, Aveta P MD, Menozzi A MD, Rossi R MD: Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001;141(1):41-46
-
(2001)
Am Heart J
, vol.141
, Issue.1
, pp. 41-46
-
-
Modena, M.G.1
Aveta, P.2
Menozzi, A.3
Rossi, R.4
|